Sep 11, 2023 / 01:20PM GMT
Vikram Purohit - Morgan Stanley, Research Division - Equity Analyst
Okay. Thank you, everyone. Appreciate that. With that, happy to have with me Mr. Mehrdad Mobasher, CMO of Hematology from BeiGene; and Mark Lanasa, CMO of Solid Tumors for BeiGene. Thank you both for joining us.
Mehrdad Mobasher - BeiGene, Ltd. - Chief Medical Officer of Hematology
Appreciate it.
Mark Lanasa - BeiGene, Ltd. - Senior VP & Chief Medical Officer for Solid Tumors
Appreciate it.
Vikram Purohit - Morgan Stanley, Research Division - Equity Analyst
Before we get into any pipeline-related and Brukinsa-related Q&A, I thought it might be good just to level set for the audience, if you could both just provide a quick overview of what you think some of the key inflection points have been across your respective areas of work at BeiGene for this year?
Mehrdad Mobasher - BeiGene, Ltd. - Chief Medical Officer of Hematology
So maybe I'll start first with
Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
